Study to investigate safety, tolerability and effect of multiple dosing with AZD 4721 and/or with AZD 5069

Study identifier:D5200C00002

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4721 after Once Daily Administration of Multiple Ascending Doses for 10 days, and an Open-label Comparison with the Pharmacodynamics of AZD5069 given Twice Daily for 3 days

Medical condition

Chronic obstructive pulmonary disease (COPD).

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD4721, Placebo, AZD5069

Sex

All

Actual Enrollment

84

Study type

Interventional

Age

18 Years - 50 Years

Date

Study Start Date: 01 Nov 2013
Primary Completion Date: 01 Jun 2014
Study Completion Date: 01 Jun 2014

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Jun 2015 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria